SourceBio International set for testing increase

SourceBio International (LON: SBI) should be publishing a trading update in the near future. The AIM-quoted diagnostics and testing company was hit by downgrades last year because of lower Covid PCR testing levels, but the emergence of Omicron has boosted demand.

The share price has recovered in the past two months, although it is still lower than one year ago. At 157.5p a share, SourceBio International is valued at £116.8m.

There should be guidance on the outcome of 2021 but more importantly there should be an indication of expectations for 2022. Last year’s figures could be slightly b...

Previous articleTeam17 simulation deal
Next articleCineworld revenues surge thanks to Spiderman
Andrew Hore is the publisher of AIM Journal, which is an online monthly publication covering the Alternative Investment Market.